151 related articles for article (PubMed ID: 12725018)
1. [The relevance of genetically determined polymorphism CYP2D6 in psychopharmacology; the relationship between genotype and phenotype].
Grzesiak M; Beszłej A
Psychiatr Pol; 2002; 36(6):869-83. PubMed ID: 12725018
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
3. No association between CYP2D6 polymorphisms and personality trait in Japanese.
Iwashima K; Yasui-Furukori N; Kaneda A; Saito M; Nakagami T; Sato Y; Kaneko S
Br J Clin Pharmacol; 2007 Jul; 64(1):96-9. PubMed ID: 17324244
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
9. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses.
Varela N; Quiñones LA; Stojanova J; Garay J; Cáceres D; Cespedes S; Sasso J; Miranda C
Pharmacol Res; 2015 Nov; 101():124-9. PubMed ID: 26211952
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
[TBL] [Abstract][Full Text] [Related]
12. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
[TBL] [Abstract][Full Text] [Related]
13. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.
Bertilsson L; Dahl ML; Dalén P; Al-Shurbaji A
Br J Clin Pharmacol; 2002 Feb; 53(2):111-22. PubMed ID: 11851634
[TBL] [Abstract][Full Text] [Related]
16. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6.
Kitada M
Int J Clin Pharmacol Res; 2003; 23(1):31-5. PubMed ID: 14621071
[TBL] [Abstract][Full Text] [Related]
18. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.
Dodgen TM; Labuschagne CJ; van Schalkwyk A; Steffens FE; Gaedigk A; Cromarty AD; Alessandrini M; Pepper MS
Pharmacogenomics J; 2016 Nov; 16(6):566-572. PubMed ID: 26503815
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.
Panserat S; Sica L; Gérard N; Mathieu H; Jacqz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1999 Jan; 47(1):121-4. PubMed ID: 10073750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
